Esteban Cvitkovic
Overview
Explore the profile of Esteban Cvitkovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1035
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Odore E, Lokiec F, Cvitkovic E, Bekradda M, Herait P, Bourdel F, et al.
Clin Pharmacokinet
. 2015 Sep;
55(3):397-405.
PMID: 26341814
Background And Objectives: OTX015 (MK-8628) is a novel inhibitor of the bromodomain and extraterminal (BET)-bromodomain (BRD) protein family, binding specifically to bromodomains BRD2/3/4 and impacting the epigenetic regulation of several...
12.
Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, et al.
Clin Cancer Res
. 2015 Jan;
21(7):1628-38.
PMID: 25623213
Purpose: In cancer cells, the epigenome is often deregulated, and inhibition of the bromodomain and extra-terminal (BET) family of bromodomain-containing proteins is a novel epigenetic therapeutic approach. Preliminary results of...
13.
Vazquez R, Astorgues-Xerri L, Bekradda M, Gormley J, Buick R, Kerr P, et al.
Biochimie
. 2014 Dec;
108:101-7.
PMID: 25446656
Degradation of extracellular matrix components is a key step in tumor progression, facilitating invasion, angiogenesis, and metastasis. The lysosomal cysteine protease cathepsin S (Cat-S) is a prominent player in this...
14.
Astorgues-Xerri L, Riveiro M, Tijeras-Raballand A, Serova M, Rabinovich G, Bieche I, et al.
Eur J Cancer
. 2014 Jul;
50(14):2463-77.
PMID: 25042151
Background: Galectin-1 (Gal1), a carbohydrate-binding protein is implicated in cancer cell proliferation, invasion and tumour angiogenesis. Several Gal1-targeting compounds have recently emerged. OTX008 is a calixarene derivative designed to bind...
15.
Zucchetti M, Bonezzi K, Frapolli R, Sala F, Borsotti P, Zangarini M, et al.
Cancer Chemother Pharmacol
. 2013 Aug;
72(4):879-87.
PMID: 23978989
Purpose: OTX008 is a galectin-1-targeting compound, currently undergoing a phase I clinical trial. This study aimed at investigating OTX008 pharmacokinetics (PK) and antineoplastic activity. Methods: Pharmacokinetics and activity of OTX008...
16.
Lovejoy K, Serova M, Bieche I, Emami S, DIncalci M, Broggini M, et al.
Mol Cancer Ther
. 2011 Jul;
10(9):1709-19.
PMID: 21750216
Pyriplatin, cis-diammine(pyridine)chloroplatinum(II), a platinum-based antitumor drug candidate, is a cationic compound with anticancer properties in mice and is a substrate for organic cation transporters that facilitate oxaliplatin uptake. Unlike cisplatin...
17.
Nowotnik D, Cvitkovic E
Adv Drug Deliv Rev
. 2009 Aug;
61(13):1214-9.
PMID: 19671439
ProLindac (AP5346) is DACH (diaminocyclohexane) platinum polymer prodrug currently in phase II clinical development. It uses a 25 kDa polymer delivery vehicle based on hydroxypropylmethacrylamide (HPMA) to target the active...
18.
Ghoul A, Serova M, Astorgues-Xerri L, Bieche I, Bousquet G, Varna M, et al.
Cancer Res
. 2009 May;
69(10):4260-9.
PMID: 19417139
Acquired resistance to protein kinase C (PKC) modulators may explain the failure of clinical trials in patients with cancer. Herein, we established a human colon cancer cell line resistant to...
19.
Serova M, Ghoul A, Benhadji K, Faivre S, Le Tourneau C, Cvitkovic E, et al.
Mol Cancer Ther
. 2008 Apr;
7(4):915-22.
PMID: 18413805
PEP005 (ingenol-3-angelate) is a novel anticancer agent extracted from Euphorbia peplus that was previously shown to modulate protein kinase C (PKC), resulting in antiproliferative and proapoptotic effects in several human...
20.
Alexandre J, Kahatt C, Bertheault-Cvitkovic F, Faivre S, Shibata S, Hilgers W, et al.
Invest New Drugs
. 2007 Jul;
25(5):453-62.
PMID: 17628744
Purpose: To determine the maximum tolerated dose (MTD), recommended dose, dose limiting toxicities (DLT), safety and pharmacokinetics of irofulven combined with capecitabine in advanced solid tumor patients. Experimental Design: Irofulven...